Tesaro wins reimbursement for Zejula in the UK through Cancer Drugs Fund

31 May 2018

Zug, Switzerland-based oncology specialist Tesaro (Nasdaq: TSRO) has received a positive reimbursement decision from the UK’s health technology assessor for Zejula (niraparib).

As overall survival data is not yet available for the therapy, it will be made available in England and Wales at first through the Cancer Drugs Fund (CDF), a dedicated fund for oncology medicines that are not reimbursed through the National Health Service (NHS).

The National Institute for Health and Care Excellence (NICE) has recommended Zejula for women with a BRCA mutation who have received two lines of chemotherapy and in women without a BRCA mutation who have received two or more lines of chemotherapy.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK